RSLS vs. DYNT, QNRX, SINT, INVO, IONM, GMVDF, BJDX, TNON, STSS, and NMRD
Should you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), Sintx Technologies (SINT), INVO Bioscience (INVO), Assure (IONM), G Medical Innovations (GMVDF), Bluejay Diagnostics (BJDX), Tenon Medical (TNON), Sharps Technology (STSS), and Nemaura Medical (NMRD). These companies are all part of the "surgical & medical instruments" industry.
Dynatronics (NASDAQ:DYNT) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
4.2% of Dynatronics shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 9.1% of Dynatronics shares are held by insiders. Comparatively, 0.1% of ReShape Lifesciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Dynatronics has higher revenue and earnings than ReShape Lifesciences.
Dynatronics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.
ReShape Lifesciences received 89 more outperform votes than Dynatronics when rated by MarketBeat users. Likewise, 66.22% of users gave ReShape Lifesciences an outperform vote while only 50.82% of users gave Dynatronics an outperform vote.
Dynatronics has a net margin of -13.07% compared to Dynatronics' net margin of -130.99%. ReShape Lifesciences' return on equity of -55.14% beat Dynatronics' return on equity.
Dynatronics presently has a consensus target price of $3.80, suggesting a potential upside of 769.76%. Given ReShape Lifesciences' higher possible upside, equities analysts plainly believe Dynatronics is more favorable than ReShape Lifesciences.
In the previous week, ReShape Lifesciences had 3 more articles in the media than Dynatronics. MarketBeat recorded 7 mentions for ReShape Lifesciences and 4 mentions for Dynatronics. Dynatronics' average media sentiment score of 0.43 beat ReShape Lifesciences' score of -0.26 indicating that ReShape Lifesciences is being referred to more favorably in the news media.
Summary
Dynatronics beats ReShape Lifesciences on 8 of the 14 factors compared between the two stocks.
Get ReShape Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ReShape Lifesciences Competitors List
Related Companies and Tools
